Published in

Elsevier, Genetics in Medicine, 4(17), p. 245-252, 2015

DOI: 10.1038/gim.2015.15

Links

Tools

Export citation

Search in Google Scholar

Navigating the current landscape of clinical genetic testing for inherited retinal dystrophies

Journal article published in 2015 by Kristy Lee ORCID, Seema Garg
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Inherited eye disorders are a significant cause of vision loss. Genetic testing can be particularly helpful for patients with inherited retinal dystrophies because of genetic heterogeneity and overlapping phenotypes. The need to identify a molecular diagnosis for retinal dystrophies is particularly important in the era of developing novel gene therapy-based treatments, such as the RPE65 gene-based clinical trials and others on the horizon, as well as recent advances in reproductive options. The introduction of massively parallel sequencing technologies has significantly advanced the identification of novel gene candidates and has expanded the landscape of genetic testing. In a relatively short time clinical medicine has progressed from limited testing options to a plethora of choices ranging from single-gene testing to whole-exome sequencing. This article outlines currently available genetic testing and factors to consider when selecting appropriate testing for patients with inherited retinal dystrophies.Genet Med advance online publication 19 March 2015Genetics in Medicine (2015); doi:10.1038/gim.2015.15.